Mr Mikel brings to the Board a strong and diverse track record in business development, commercial leadership, capital markets, and strategic partnership execution across the Medtech, diagnostics, healthcare services, and life sciences sectors.
He has held senior executive and board positions in both listed and private companies, with extensive experience in the commercialisation of disruptive technologies and scaling ventures in regulated markets.
He is currently the CEO and Managing Director of Vitasora Health Limited (ASX: VHL), an ASX-listed remote patient monitoring (RPM) company operating in the U.S. healthcare system. Under his leadership, the company has pioneered the commercialisation of a novel respiratory monitoring device and successfully transitioned into a full-service RPM provider. Mr Mikel led capital raises, secured major U.S. ACO and payer contracts, and executed the cross-border acquisition of U.S.-based Orb Health, expanding the company’s footprint and capabilities in the U.S. market.
Previously, Mr Mikel founded Healthy Sleep Solutions, building it into Australia’s largest sleep health provider before securing ResMed as a strategic investor and leading a successful trade sale to global multinational Air Liquide. He also held senior commercial roles with IMS Health, Merck Sharp & Dohme, Pharmacia, and Searle, with responsibilities across Australia, Asia-Pacific, and Europe.
Importantly, Mr Mikel is familiar with Memphasys and its strategic vision, having previously served as a Non-Executive Director of the Company from June 2018 to March 2020, including as Chair of both the Audit & Risk Committee and the Nomination & Remuneration Committee.
Mr Mikel holds a Master of Commerce from the University of New South Wales, a Graduate Diploma in Education and a Bachelor of Science (Hons) from the University of Sydney and has completed executive studies at the Australian Graduate School of Management. He is also a Member of the Australian Institute of Company Directors (MAICD).
He is Chair of the Commcercialisation Committee.